CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 74 enrolled
Drug / intervention
Lumenis VersaCut Morcellator +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02195622
NCT02195622N/ACompleted
CompareCT.gov

Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures

Indiana Kidney Stone Institute·interventional·Posted Jul 21, 2014·Updated Mar 11, 2019

In Brief

A clinical study evaluating Lumenis VersaCut Morcellator and Wolf Piranha Morcellator for Benign Prostatic Hypertrophy Requiring Surgical Intervention. Completed, enrolled 74 participants across 1 site.

Detailed Summary

To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic hyperplasia (BPH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hypertrophy Requiring Surgical Intervention
CountriesUnited States
CollaboratorsRichard Wolf Medical Instruments Corporation (RWMIC)

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 21, 2014
Enrollment StartSep 1, 2013
Primary CompletionJan 1, 2015
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.9 years ago

Interventions

Lumenis VersaCut Morcellatordevice

Wolf Piranha Morcellatordevice